Purdue Pharma LP
Quick facts
Marketed products
- Subutex · Neuroscience · revenue 800
Buprenorphine binds to mu-opioid receptors as a partial agonist and kappa-opioid receptors as an antagonist. - Adhansia XR · Neurology / Psychiatry
Adhansia XR is a combination of amphetamine salts and guanfacine that increases dopamine and norepinephrine activity while also activating alpha-2A adrenergic receptors to improve attention and reduce hyperactivity and impulsivity. - Buprenorphine transdermal patch
- HYD · Pain Management
Hydrocodone is an opioid agonist that binds to mu opioid receptors in the central nervous system to produce analgesia and cough suppression. - Chirocain · Pain
- Oxycodone HCl controlled-release · Pain Management
Oxycodone HCl binds to opioid receptors in the central nervous system to block pain signal transmission and produce analgesia.
Phase 3 pipeline
- Buprenorphine transdermal delivery system · Pain Management; Opioid Use Disorder
Buprenorphine is a partial mu-opioid receptor agonist that binds with high affinity to opioid receptors in the central nervous system to produce analgesia and reduce opioid cravings. - OXY/APAP · Pain Management
OXY/APAP combines oxycodone (an opioid analgesic) with acetaminophen (a non-opioid analgesic) to provide enhanced pain relief through dual mechanisms. - Oxycodone HCl controlled-release tablets · Pain Management
Oxycodone HCl binds to opioid receptors in the central nervous system to block pain signal transmission and provide analgesia. - Oxycodone/Naloxone controlled-release · Pain Management
Oxycodone/naloxone is a controlled-release opioid analgesic combined with an opioid antagonist designed to provide pain relief while reducing abuse potential. - Placebo oxycodone/acetaminophen tablets · Pain Management
This is a placebo formulation containing no active pharmaceutical ingredients, used as a control in clinical trials to establish the true efficacy of oxycodone/acetaminophen combination therapy. - Placebo to match BTDS
This drug is a placebo that matches BTDS, meaning it has no active pharmacological effect.
Phase 2 pipeline
- Ketoconazole tablet · Infectious Disease
Ketoconazole is a broad-spectrum antifungal agent that inhibits the synthesis of ergosterol, a vital component of fungal cell membranes, by blocking the cytochrome P450-dependent enzyme lanosterol 14α-demethylase. - Naloxone HCl intranasal
- V116517 30-mg tablets
- V116517 50-mg tablets
- V120083
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: